NSCLC is the largest disease segment in the global lung cancer therapeutics market and is expected to increase by 83% by 2020, says Technavio.
Technavio has announced its latest market research report on lung cancer therapeutics for the forecast period, 2016-2020. This market analysis, under the oncology vertical, discusses the major drivers and key emerging trends that will influence the growth of the global lung cancer therapeutics market during the forecast period. Some of the top vendors listed in this industry analysis include F. Hofmann-La Roche, Eli Lilly, AstraZeneca, Pfizer, and Celgene.
Among various geographical regions, the Americas will be the fastest-growing region in the global market, and is expected to contribute around $6 billion by 2020. The US is the largest contributor of the region due to the presence of multiple treatment options, refined drug delivery technologies, and increased accessibility to treatment therapies because of patient assistance programs.
“Researchers are focused on developing new therapeutics such as miRNA therapeutics to meet the medical needs. miRNA therapeutics are therapeutic candidates that can repress multiple oncogenic pathways at once. The recent discovery of miRNAs revealed a novel mechanism for post-transcriptional regulation in lung cancer and presents new opportunities for the diagnosis, prognosis, and targeted therapeutics,” says Sapna Jha, a lead analyst at Technavio for research on oncology.
Click here to request a free sample of this report
This new industry research report from Technavio analyzes some of the key drivers and trends responsible for the growth of this market and its sub-segments.
Growing demand for targeted therapies
Targeted therapy is a treatment that targets genes, cells, cancer-specific proteins, or the tissues that lead to cancer growth and survival. The market has been witnessing a growing demand for targeted therapies, which is likely to drive market growth. The demand for targeted therapies is due to its greater efficiency over the conventional therapies such as platinum-based chemotherapy, radiation therapy, and surgical resection. The major vendors in the market have focused on developing targeted therapies in combination with the traditional ones. Further, targeted therapies may have lesser side effects as compared to chemotherapy and radiation. The common gene changes in NSCLC, that have targeted therapies approved by the US FDA, are epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK). Some of the drugs that target EGFR include Gilotrif, Iressa, Tarceva, Portrazza, and Tagrisso, while ALK-targeting drugs include Xalkori, Alecensa, and Zykadia.
Presence of blockbuster drugs coupled with longer patent exclusivities
The global lung cancer therapeutics market consists of established therapies, which are primarily driving the market growth. Some of the established drugs include Avastin, Gemzar, Xalkori, and Abraxane. These therapies have a proven relationship with the physicians due to their established clinical profile. Moreover, the longer patent exclusivities for these drugs are expected to generate substantial revenues, thereby driving the market growth.
Advancements in identification of molecular biomarkers increasing patient pool
The advent of new molecular biomarkers, which helps improve the diagnosis rates of lung cancer, is increasing the patient population which will add further revenue to the market. Currently, the mutation status remains unknown in approximately 50% of the cases, which are linked to one of the ten currently-known molecular biomarkers. With the help of biomarkers, the diagnosis rates will increase, leading to the enhanced patient pool. Moreover, researchers have identified over 15 genetic mutations that cause lung cancer. More than 50% of adenocarcinoma cases have an identifiable molecular driver allowing the cancer cells to grow. The molecular drivers also help in guiding the treatment decisions. The testing for clinically appropriate biomarkers during treatment planning becomes important to individuals with metastatic NSCLC. Such growing research activities will improve the quality of diagnosis tests.
Some of the other prominent vendors identified in this report are Abbvie, Aetna, Agennix, Allergan, Amgen, ARIAD Pharmaceuticals, Astellas Pharma, Betta Pharmaceuticals, BeyondSpring Pharmaceuticals, BioNumerik Pharmaceuticals, Boehringer Ingelheim, Boston Biomedical, Bristol-Myers Squibb, Celldex, CTI BioPharma, Eisai, GlaxoSmithKline, GTx, Helsinn, Hutchison Medipharma, Ionis Pharmaceuticals, Kadmon Corporation, MabVax, Merck, Novartis, NovaRx Corporation, OncoGeneX, Ono Pharmaceutical, OSE Immunotherapeutics, OSI Pharmaceuticals, Peregrine, PharmaMar, Pierre Fabre, Qiagen, Recombio, Samsung Bioepis, Sanofi, SFJ Pharmaceuticals, Spectrum Pharmaceuticals, Sumitomo Dainippon Pharma, Synta, Takeda Pharmaceuticals, Teva Pharmaceutical, and Xcovery.
This research report includes an in-depth analysis, market shares, and sizes of the sub-segments and geography. It provides a comprehensive analysis of the key companies, including their market shares, business overview, and key financials. The market study also offers a detailed analysis of key drivers, challenges, and opportunities influencing this market.
A more detailed analysis is available in the Technavio report titled, ‘Global Lung Cancer Therapeutics Market 2016-2020‘. Technavio also customizes reports by other regions and specific segments upon request.
Other related reports:
- Global Small Cell Lung Cancer Therapeutics Market 2015-2019
- Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019
- Global Cancer Diagnostic Devices Market 2016-2020
- Solid Tumor Testing Market in the US 2016-2020
To read more press releases- click here.
For any assistance or query, please contact our media team at:
media@technavio.com
US: +1 630 333 9501
UK: +44 208 123 1770
https://www.technavio.com/
